HuanWai Pharmaceutical

Beijing Huanwai Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company's primary focus is on the DNA damage response (DDR) pathway and synthetic lethality, aiming to overcome resistance to existing cancer treatments. Its lead candidate, HW001, is a highly selective inhibitor of Ubiquitin-Specific Protease 1 (USP1) currently in Phase 1 clinical trials for advanced solid tumors. Huanwai Pharmaceutical is supported by a strong network of venture capital investors, including GL Ventures and Qiming Venture Partners. The company maintains a robust research and development infrastructure to advance its pipeline of novel cancer therapies.